ReViral drug discovery for RSV 

ReViral is a UK-based biotechnology company developing first in class drugs to treat RSV infections.

• ReViral is developing a fusion inhibitor of RSV which is a highly potent, novel small molecule
• Fusion inhibitor is a highly potent small molecule
• ReVirals most advanced programme is in phase 1 clinical trials
• ReVirals pipeline also includes inhibitors of RSV replication

Upcoming Events

June 19–22, 2017
BIO International Convention
San Diego 

Nov 6-8, 2017
BioEurope
Berlin

Jan 8-10, 2018
Biotech Showcase
San Francisco